Bohle Fluid Bed Sytsem BFS - Bohle Uni Cone BUC® - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Bohle Fluid Bed Sytsem BFS - Bohle Uni Cone BUC®

With the Bohle Uni Cone BUC ® process, L.B. Bohle can protect a new development method for precise coating of particles as a utility model right now. “This method works much more accurately and evenly than the conventional Wurster process”, says the CEO Lorenz Bohle.

The Wurster process is used, when small particle, so called pellets, must be coated. Biggest weaknesses are hardly calculable setting parameters and the spray nozzles in the bottom.

"We have developed two major changes that solve both problems of the Wurster process", says Bohle. A sloping floor and a conical tip in the center provide a uniform turbulence of the product. Simultaneously, the coating substance is spray to lateral nozzles. "We thus reach a hitherto possible coating uniformity, the losses are under one percent in a very complex process", said Bohle. Furthermore the Bohle Uni Cone BUC ® guarantees high yields in the final product due to absence of particle twinning effects. "The losses are under one percent in a very complex process."

The tangential nozzles have also enhanced quality advantages in handling.

By this reasons using the tangential BFS represents state of the art in pharmaceutical manufacturing for particle coating, granulation and drying.

Contact information:

Tobias Borgers
Head of Marketing
t.borgers@lbbohle.de
+49 2524 – 9323 150
+49 2524 – 93 23 399
www.lbbohle.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here